Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deciphering Bangladesh’s Agile Supply Deal For AZ/Serum Vaccine

Beximco Harboring Manufacturing Ambitions?

Executive Summary

Senior Beximco executive outlines details, including pricing nuances, of a deal with the Serum Institute of India for the supply to Bangladesh of the AstraZeneca/University of Oxford coronavirus vaccine. Will India’s neighbor also benefit from pricing adjustments?

You may also be interested in...



Initial $4.8bn Outlay To Back India's COVID-19 Vaccination Run

Significant allocations for public health programs and vaccination are prominent features of India's budget for fiscal 2021-22, though execution of these plans will be critical. Pharma is also keenly tracking a proposed allocation to bolster the overall research ecosystem and opening up of the insurance sector to foreign ownership.

Beximco Takes Control Of Sanofi Bangladesh

Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.

Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To ‘Follow Science’ In Vaccine Trials

The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel